Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04375150 · ClinicalTrials.gov registry record
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 355
- Enrollment target
NCT04375150 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 355 participants.
The verdict
NCT04375150 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 355 participants
- Enrollment target
Study Summary
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
Interventions
- DRUG Tyrosine kinase inhibitor (TKI)
- DRUG Immuno-oncology (IO)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 355 participants |
| Start Date | 2019-12-02 |
| Est. Completion | 2022-10-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04375150
The ClinicalTrials.gov registry entry for NCT04375150 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 355 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tyrosine kinase inhibitor (TKI) is the first listed.
NCT04375150 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04375150 about?
NCT04375150 is a clinical study titled "Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC". The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
What is the current status of trial NCT04375150?
This trial is currently completed. The enrollment target is 355 participants. The study started on 2019-12-02. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT04375150?
The interventions under investigation include: Tyrosine kinase inhibitor (TKI) (DRUG), Immuno-oncology (IO) (DRUG).
Who is sponsoring clinical trial NCT04375150?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.